Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DB-1317
- Development stage
- Phase 1
- Lead developer
- Duality Biotherapeutics
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
**DB-1317** is an investigational antibody-drug conjugate (ADC) developed for the treatment of advanced or metastatic solid tumors. It is currently under evaluation in a multicenter, open-label, first-in-human (FIH) Phase 1a/1b clinical trial to determine its maximum tolerated dose (MTD), safety, tolerability, and preliminary efficacy. The drug targets *ADAM9*, a protein associated with tumor progression, and uses an ADC approach to deliver a cytotoxic payload selectively to cancer cells expressing this protein. The primary indication in clinical trials includes gastric cancer (GC), colorectal cancer (CRC), and pancreatic ductal adenocarcinoma (PDAC), focusing on patients who have relapsed or progressed after standard systemic treatments. The developer, DualityBio, has positioned DB-1317 as part of its next-generation ADC clinical pipeline, with dose escalation and randomized dose expansion cohorts currently underway[1][2][4].
- Brand names
- DB-1317DB1317DB 1317
- Other names
- DB-1317DB1317DB 1317
02
Targets
ADAM9
Beyond the preview
Go deeper on DB-1317.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DB-1317.